A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands

Background: We conducted a post-hoc analysis of a double blind, randomized, placebo-controlled trial of 13-valent pneumococcal conjugate vaccine (PCV13) among adults aged 65 years or older to assess public health impact. Methods: For all outcomes, we included all randomized subjects, using a modified intention-to-treat (mITT) approach to determine vaccine efficacy (VE), vaccine preventable disease incidence (VPDI) defined as control minus vaccinated group incidence, and numbers needed to vaccinate (NNV) (based on a five-year duration of protection). Results: Results are reported for, in order,... Mehr ...

Verfasser: Gessner, Bradford D.
Jiang, Qin
Neuzil, Kathleen M.
Dokumenttyp: Artikel
Erscheinungsdatum: 2018
Verlag/Hrsg.: Elsevier Ltd
Schlagwörter: pneumococcal conjugate vaccine
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26822581
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://hdl.handle.net/10713/9844